CA-VERIMATRIX
24.6.2024 17:46:27 CEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today announced its participation in two leading events organized by the Open Worldwide Application Security Project (OWASP). The following conferences will showcase the award-winning Verimatrix Extended Threat Defense (XTD) mobile app security solutions:
-
OWASP Global AppSec Lisbon 2024 – June 24-28, 2024
Lisbon Congress Centre – Lisbon, Portugal
https://lisbon.globalappsec.org/
-
OWASP Global AppSec San Francisco 2024 – September 23-27, 2024
Hyatt Regency San Francisco – San Francisco, California
https://sf.globalappsec.org/
Bringing together those tasked with ensuring proper security for apps, the associated enterprise, as well as their app users, OWASP events serve as leading venues to illustrate the value and differentiation that comes with proactively deploying mobile app protections. Verimatrix XTD mobile app security solutions quickly and easily provide the robust protection, monitoring and remediation that app manufacturers require to combat today’s latest threats.
“As a proud OWASP member company, and a diamond sponsor for the event in Lisbon and a silver corporate supporter in San Francisco, Verimatrix believes OWASP’s conferences provide valuable contributions to the mobile industry,” said Tom Powledge, Head of Cybersecurity Business for Verimatrix. “We’re pleased to participate and exhibit so that we can share the successes Verimatrix XTD has helped enable, and help guide developers through the daunting regulatory compliance hurdles many of them face when trying to launch and maintain their apps.”
Verimatrix XTD has become the go-to cybersecurity solution for organizations that must shield their Android applications from reverse engineering and other cyberattacks due to compliance regulations. Setting itself apart within the industry, Verimatrix offers flexible deployment options including zero-code cloud solutions, on-premises toolkits, and a white glove service whereby Verimatrix’s team of expert threat intelligence account managers ensures cybersecurity defenses are efficiently implemented into DevSecOps workflows, as well as into continuous integration and deployment (CI/CD) processes on behalf of customers, which is especially useful for companies with limited cybersecurity staff or expertise in combatting mobile app attacks.
Verimatrix XTD protects mobile app owners from a wide range of threats such as supply chain attacks, screen overlays, application repackaging, illicit modification or tampering, man-in-the-device attacks, and more. Its advanced obfuscation techniques, as well as its threat detection and response capabilities using AI/ML, put XTD into an enterprise class like few others.
Verimatrix XTD’s family of application protection solutions include:
- XTD Enterprise Suite
- XTD Protect for Mobile (iOS and Android)
- XTD Protect for Desktop and Embedded Applications (Windows, MacOS and Linux)
- XTD Protect for Native Applications (C/C++)
- XTD Key Shield (whitebox cryptography)
- XTD Protect for Web Applications
- XTD Managed Services
For more information on Verimatrix XTD or to schedule a product demo visit VerimatrixCybersecurity.com.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624123584/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
